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Interpreting Adverse Signals in
Diabetes Drug Development Programs
CLIFFORD J. BAILEY, PHD
Detection and interpretation of adverse signals during preclinical and clinical stages of drug
development inform the beneﬁt-risk assessment that determines suitability for use in real-world
situations. This review considers some recent signals associated with diabetes therapies, illus-
trating the difﬁculties in ascribing causality and evaluating absolute risk, predictability, preven-
tion, and containment. Individual clinical trials are necessarily restricted for patient selection,
number, and duration; they can introduce allocation and ascertainment bias and they often rely
on biomarkers to estimate long-term clinical outcomes. In diabetes, the risk perspective is in-
evitably confounded by emergent comorbid conditions and potential interactions that limit
therapeutic choice, hence the need for new therapies and better use of existing therapies to
address the consequences of protracted glucotoxicity. However, for some therapies, the adverse
effects may take several years to emerge, and it is evident that faint initial signals under trial
conditions cannot be expected to foretell all eventualities. Thus, as information and experience
accumulate with time, it should be accepted that beneﬁt-risk deliberations will be reﬁned, and
adjustments to prescribing indications may become appropriate.
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Development of a new pharmacother-apy typically follows a sequence ofpreclinical and clinical stages
(Table 1). Completion of phase 3 marks
the accumulation of clinical experience
used to prepare an application formarket-
ing authorization by a regulatory agency
such as the Food and Drug Administra-
tion (FDA) or European Medicines Ag-
ency (EMA). This application should
provide evidence for an adequately favor-
able beneﬁt-risk balance for the intended
use (1). Detection and interpretation of
adverse properties during the develop-
ment program are critical components
of the authorization decision and guide
the labeling and postmarketing obliga-
tions. The main safety questions raised
about diabetes therapies are summarized
in Table 2. This review examines the in-
terpretation of adverse signals associated
with recently approved blood glucose–
lowering agents.
PREAPPROVAL CLINICAL
TRIALSdThe journey from molecule
to medicine is likely to take at least 10
years for a new class of agent and to cost
;$500 million (1–3). If the many unsuc-
cessful drug discovery studies and early
development programs are factored in,
the average approved drug probably re-
ﬂects $1.3–1.8 billion of investment, so
there is a strong incentive to secure mar-
keting authorization once an agent has
progressed through phase 3 (2,3). For a
new diabetes medication, phase 3 usually
takes ;3 years and consumes up to 90%
of the total development costs; hence, an
agent that is entered into phase 3 has in-
variably passed very thorough scrutiny of
phase 2 efﬁcacy and safety data and an
assessment of marketing potential. Phase
3 customarily involves a minimum of
1,500 patients treated with the test agent
(Table 3), generating 1,000–3,000 pa-
tient-years of exposure and a database
from which to consider beneﬁts and risks
for a real-world setting (4,5).
DETERMINING BENEFITS AND
RISKSdAlthough it is well recognized
that early and sustained reductions of
HbA1c markedly reduce microvascular
complications and may contribute to re-
duced macrovascular risk, about one-half
of diabetic patients still do not achieve or
maintain sufﬁcient glycemic control to
avoid substantial long-term morbidity
(6–10). New types of glucose-lowering
agents are particularly required for type
2 diabetes because of the multivariable
mix of genetic and environmental factors
that conspire to create a progressive and
highly heterogeneous natural history,
with at least eight major organ systems
being etiopathogenically implicated (11).
With regard to beneﬁt, it is unlikely
that an agent will be submitted for mar-
keting authorization if it does not meet
recognized approvable efﬁcacy criteria.
The generally accepted efﬁcacy surrogate
is a reduction in HbA1c that is commen-
surate with the baseline HbA1c of the
patient population studied (greater im-
provements of glycemic control expected
if higher baseline hyperglycemia), taking
into account the concomitant health is-
sues within that population and additional
beneﬁts of the agent (12). The favorable–
unfavorable boundary of beneﬁts and
risks will reﬂect whether efﬁcacy is com-
parable with or better than existing thera-
pies, achieved by a new mode of action
that can be substituted for or add com-
patibly to these therapies, or assist sub-
populations and comorbid conditions
inadequately served by existing therapies.
Set against this, we have the frequency and
severity of apparent adverse effects, their
predictability, potential avoidance, mini-
mization or rectiﬁcation, and practicalities
of identifying and containing risk during
real-world usage. Beyond this, theoretical
adverse effects might be contemplated
with regard to mode of action or other
known pharmacodynamic or pharmaco-
kinetic properties (4,5,12).
Preregistration trials are mostly de-
signed and powered for a primary efﬁcacy
end point, customarily a reduction in
HbA1c over 6 months at two or more dos-
age strengths (Table 3). As durability of
efﬁcacy receives more attention, extended
randomized controlled trials are envi-
sioned, with greater use of add-on rescue
therapy to enable prolonged double
blinding, and greater acceptance of post
hoc analyses may be required. However,
there will always be a desire for more drug
exposure to assess risk, especially that
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pertaining to more vulnerable subpopu-
lations. This raises the issues of preregis-
tration meta-analyses of trial data and the
role of postmarketing studies.
Relative risk against a placebo or com-
parator (or sometimes compared with a
separate study of similarly disposed pa-
tients) provides a convenient indicator for
interpreting frequency and severity of
adverse signals, but absolute risk is per-
haps more likely to interest the patient
and prescriber. Figure 1 illustrates the
absolute risk (per 1,000 patient-years)
for fatal and major comorbid complica-
tions of diabetes alongside various reported
adverse events attributed to diabetes
pharmacotherapies (13–28). This per-
spective hopefully will rationalize the in-
evitable limitations of a preregistration
trial database as a ﬁrst step for ongoing
surveillance to identify uncommon, rare,
or slowly emerging adverse properties,
including long-term risks of fatal, life-
threatening, or permanently disabling
events (13). Tolerability and quality of
life may not be strictly within the remit
of safety, but they are issues that affect
adherence and impinge on beneﬁt-risk
deliberations.
Because diabetes is for life, comorbid
conditions are rife, and therapies mostly
last for much longer than the trial periods,
the rigorous safety cautions for a new
drug approval often require a compre-
hensive postmarketing risk management
program to accompany standard pharma-
covigilance monitoring (5). These can in-
clude small studies in special populations
and crucial attention to issues of suspi-
cion from preregistration signals, such
as trends in biomarkers together with
safety-ﬁrst labeling restrictions. Accepting
a caveat for the unpredictable, black box
warnings can serve a valuable precaution-
ary role to minimize misuse.
HYPOGLYCEMIAdTreatment with
antidiabetic drugs commonly produces
mild hypoglycemic symptoms, especially
with insulin, sulfonylureas, or combina-
tions involving these classes (29). Signs of
moderate or severe hypoglycemia and extra
risks associated with patient unawareness
or use in vulnerable groups, such as the
elderly or renally impaired, are well re-
hearsed in product labeling and education
packages. Nevertheless propensity for hy-
poglycemia forms an integral part of the
calculation of acceptable risk for all diabe-
tes pharmacotherapies (12). Where clini-
cally signiﬁcant risk is anticipated with
combination therapy, this is typically min-
imized by recommending down-titration
of the existing agent to coincide with the
addition of the new agent. The interpreta-
tion of hypoglycemic events is usefully
assisted by mode-of-action studies,
particularly for agents that raise in-
sulin concentration, to check whether
the already-impaired counterregulatory
capability in diabetic hypoglycemic states
is further compromised (30).
Unfortunately, the quantiﬁcation of
hypoglycemic risk in clinical trials
Table 1dStages in the development of a new drug
Preclinical stages
New chemical entity (NCE)
Preclinical phases Identiﬁcation, extraction and/or synthesis, chemical
characterization, and patenting of compounds
Genotoxicity testing. Screening for biological activity
in vitro and in vivo in animals
Preclinical pharmacology, mode of action,
pharmacodynamics (activity, safety, tolerance),
pharmacokinetics (bioavailability, distribution,
metabolism, elimination), and toxicity in two or
more mammalian species
Clinical stages
Investigational new drug (IND)
application: permission to
begin clinical studies
Phase 1 First administration to a small number of healthy
human volunteers. Dose ranging, vital signs,
pharmacodynamics, pharmacokinetics, drug
interactions, safety
Phase 2 First trials in small numbers of patients. Dose ranging,
efﬁcacy, further pharmacodynamics,
pharmacokinetics and safety
Phase 3 Trials in larger numbers of patients. Multicenter trials,
comparative trials with other treatments, efﬁcacy,
further pharmacodynamics and safety (including
meta-analysis of CV outcomes)
New drug application (NDA):
permission to market as a drug
Phase 4 Use in medical practice. Additional trials (similar to
phase 3), postmarketing surveillance, adverse
events reporting, use in special subgroups (e.g.,
elderly people)
Table 2dSafety cautions and questions raised about current diabetes therapies
Agent Cautions and questions
Metformin Lactic acidosis
Sulfonylureas Hypoglycemia, CV risk
Thiazolidinediones Aggravation of congestive heart disease and risk of fractures with
rosiglitazone and pioglitazone; bladder cancer with pioglitazone;
CV events with rosiglitazone
DPP-4 inhibitors Pancreatitis
GLP-1 receptor agonists Pancreatitis, thyroid C cells, heart rate/QTc
Insulin Hypoglycemia, tumor growth
This table notes some safety cautions and questions raised with regard to current diabetes therapies. As noted
in the text, some of these concerns are unproven or do not necessarily apply to all agents within a class. For
example, data available at the time of writing have not supported an increased risk of pancreatitis with DPP-4
inhibitors or an increased risk of pancreatitis, thyroid C-cell cancer, or QTc changes with GLP-1 receptor
agonists. Evidence associating sulfonylureas with increased CV risk remains equivocal, and data pertaining to
pioglitazone and bladder cancer are open to variable interpretations. Consideration of beneﬁt-risk balance for
insulin therapy is discussed in the text.
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continues to lack conformity, making it
difﬁcult to compare rates of hypoglycemia
between studies. Nonsevere hypoglyce-
mia might include symptoms or signs that
are self-managed by the patient with or
without a blood glucose measurement of
,70 mg/dL (,3.9 mmol/L) down to 50
mg/dL (2.8 mmol/L). Severe hypoglyce-
mia is usually distinguished by the in-
volvement of third-party assistance or a
blood glucose measurement of ,54 mg/dL
(,3 mmol/L). However, whether the
patient requires (as opposed to requests)
this assistance is often vague, and it is
sometimes difﬁcult to obtain a blood
glucose measurement at these times.
A further problem is nocturnal hypogly-
cemia, which may pass unrecognized
unless inconveniently interrupted with
a wake-up and a glucose test (29). Thus,
small differences in nocturnal hypogly-
cemia reported during comparator insu-
lin trials cannot be overinterpreted when
assessing hypoglycemic risk for licens-
ing purposes (12). A combined analysis
of data from several trials can be useful
for this purpose, but conﬁrmation re-
quires a continuous glucose monitoring
study.
WEIGHT CHANGESdAlthough in-
creased adiposity with insulin, sulfony-
lureas, and thiazolidinediones is sometimes
overlooked as a risk factor, the escalation in
vascular susceptibility that accompanies
coexistent diabetes and obesity is a quanti-
ﬁable and important component of overall
risk (31). Additionally, rapid weight gain
may signal issues other than adiposity,
such as ﬂuid retention with thiazolidine-
diones (32). The trade-off between im-
proved glycemic control and adipose
weight gain is a perennial treatment co-
nundrum for which only individualized ad-
vice can be recommended, bearing in mind
that dietary measures to counter the weight
gain can aggravate susceptibility to hypo-
glycemia (33). Rapid initial weight loss
during a clinical trialmay lead to a detection
bias for certain tumors, as discussed in a
subsequent section of this review (34,35).
CARDIOVASCULAR
RISKdBecause cardiovascular (CV)
diseases are highly prevalent and the
most common cause of premature death
among individuals with diabetes (Fig. 1),
considerable attention has been directed
toward CV risk assessment and minimi-
zation. However, being able to attribute
causality to events that are not unexpected
in the diabetic population is not a precise
science (7). To illustrate the difﬁculties, we
can reﬂect on the University Group Diabe-
tes Program (UGDP) study of the 1960s.
Although this brought to attention the
lactic acidosis issue with phenformin
(prompting further investigation that led
to the ﬁrst diabetes drug withdrawal by
the FDA in 1978), it also initiated concern
about possible detrimental CV effects of
sulfonylureas (36). Despite a further 4
Table 3dTypical phase 3 development program of clinical trials for an oral blood glucose–




Monotherapy in drug-naïve patients Placebo 24 2–4
Add-on therapy in patients already treated
with one or two glucose-lowering agents Add-on placebo 24 1–4
Add-on therapy in patients already treated
with one or two glucose-lowering agents
Add-on comparator
glucose-lowering agent 24–104 1–2
Mono- or add-on therapy to existing therapy
in patients with special requirements,
e.g., renal or hepatic impairment Placebo or comparator 12–24 1–4
These studies are normally prospective randomized double-blinded controlled trials, and the primary end
point is likely to be a change in the HbA1c value compared with baseline, placebo, or comparator agent.
Numbers will vary depending on whether superiority or noninferiority is sought but will typically be in the
range 80–150 subjects per arm. Secondary end points are likely to include changes in fasting plasma glucose
level and body weight. Studies involving add-on therapy to existing agents, especially insulin, may involve
adjustments to the dosage of the existing agent before and/or during the trial. Safety data will be collected
from all studies. Studies comparing injected agents may not be blinded, and extension studies may be un-
blinded or use strict rescue criteria to remain blinded.
Figure 1dRisk of diabetes complications and adverse events associated with diabetes drug therapies
expressed as absolute risk per 1,000 patient-years. Black bars show representative values for risk in
diabetic patients, and gray bars indicate excess risk of events in patients treated with speciﬁc glucose-
loweringmedications relative to diabetic patients receiving comparator therapies. Incidence rates are
subject to considerable variation with age, duration of diabetes, and concomitant morbidity. Adapted
with permission from Bergenstal et al. (13). Data were derived from references 13–28. ACCORD,
Action to Control Cardiovascular Risk in Diabetes; CHF, congestive heart failure; PVD, peripheral
vascular disease; UKPDS, U.K. Prospective Diabetes Study.
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decades of very extensive usage and end-
less clinical trials and database analyses,
the overall balance of evidence is still
equivocal (13). Previous accusations that
insulin is atherogenic have since been dis-
missed, but they complicated risk assess-
ments in a bygone era (37). They also
remind us that treatments that sustain
life expectancy among patients in poor
general health can result in emergent dis-
ease-related morbid conditions that
should not be confused with iatrogenic
morbid conditions.
Interpreting adverse CV signals was
brought to the fore with rosiglitazone,
which after almost 10 years of postmar-
keting experience, created sufﬁciently
ambiguous adverse event data that the
drug was withdrawn in Europe, but the
FDA settled for tighter labeling (38,39).
Although relevant CV event data were
available in the GlaxoSmithKline clinical
study register website and received upda-
ted evaluation by regulatory agencies
(40), it was a meta-analysis in the New
England Journal of Medicine that attracted
attention (26). With data from 42 ran-
domized trials, excluding six studies in
which there were no CV events, this anal-
ysis reported that rosiglitazone was asso-
ciated with an increased odds for
myocardial infarction (MI) (odds ratio
1.43, 95% CI 1.03–1.98) and CV death
(1.64, 0.98–2.74). Expressed as events/
total patients for rosiglitazone versus con-
trol groups, these odds ratios correspon-
ded to 86/14,372 versus 72/11,634 for
MI and 39/10,936 versus 22/9,509 for
CV deaths. The analyses have been re-
peated and debated extensively elsewhere
(41,42) and will not be reiterated further
here, but some generic lessons for inter-
preting signals during development pro-
grams are highlighted. When the FDA
advisory committee initially deliberated
the new drug application for rosiglita-
zone, there were data on CV events from
ﬁve randomized trials. The occurrence of
MI was 6/1,967 and 3/793 for the rosigli-
tazone and control groups, respectively,
corresponding to 0.30 and 0.37%, re-
spectively. The occurrence of CV deaths
was 2/1,967 and 0/793 for the rosiglita-
zone and control groups, respectively. So
there was no obvious signal, and bio-
marker data tended to be positive, al-
though ﬂuid retention, edema, risk of
heart failure, and weight gain were duti-
fully considered. At the time, attention
was distracted toward the liver because
another thiazolidinedione, troglitazone,
was in the spotlight for idiosyncratic hep-
atotoxicity (43). With regard to the ap-
proval of thiazolidinediones, Europe
evaluated these agents a little later and
made approvals for second-line indica-
tion (unless metformin was not appropri-
ate) and excluded New York Heart
Association class I–IV (vs. ﬁrst-line ap-
proval and exclusion of New York Heart
Association class III and IV by the FDA).
The rosiglitazone experience prompted
the FDA to issue new guidance about CV
risk (44). This requires a meta-analysis of
important CV events in phase 2/3 to
achieve an upper 95%CI of,1.3 to qual-
ify for approval without requiring a post-
marketing CV trial, provided that overall
beneﬁt and risk support approval (Fig. 2).
If the upper 95% CI is .1.8, additional
phase 3 safety studies are required before
resubmission for marketing authorization.
If the upperCI lies between 1.3 and 1.8 and
approval is otherwise appropriate, then a
postmarketing CV events study generally
will be necessary and required to show an
upper 95% CI of ,1.3. In practice, each
sponsor of recently approved drugs has
elected to undertake such a study (or
have been encouraged to do so by the
FDA), even if the phase 2/3 CV events con-
form to an upper 95% CI ,1.3. Indeed,
such postmarketing studies appear to be
almost obligatory because no sponsor com-
pany would wish for its product to be
disadvantaged in years to come if its
competitors can claim hard end point CV
data from large purpose-designed trials.
These studies, which are currently ongo-
ing, are summarized in Table 4 (45). Al-
though they are mostly event driven,
differences in estimated event rates and
duration, selection of major CV events,
power calculations, types of statistics (su-
periority vs. noninferiority), and use of
placebo, an active comparator, or both
make direct comparisons between studies
difﬁcult.
Effective use of antihypertensive and
lipid-controlling medications has re-
duced the rates for major adverse CV
events among diabetic patients (46),
which in turn will affect the spread of
CIs in an analysis of CV events, especially
in phase 2/3 studies, where the hypothet-
ical wonder drug with no events would
defy the statistical analysis. To boost
event rates, the recruitment of extra pa-
tients at high CV risk may alter the pri-
mary–secondary preventive balance of
the risk assessment. The importance of
time in the generation of CV events
must also be borne in mind because
events occurring early in trials may more
strongly reﬂect the accumulated risk in
the months and years before trial entry
rather than reﬂect the initial effects of
the test drug. For example, in a more re-
cent analysis of the rosiglitazone CV event
data, it is evident that short-term trials
give very different and far-worse out-
comes than longer-term studies (47).
Moreover, several large trials of glycemic
intensiﬁcation have found that CV event
rates are initially worse before they sub-
sequently show beneﬁt (48,49), whereas
others suggest a possible association be-
tween CV events and the extent and speed
of intensiﬁcation (7).
Dealing with CV changes that are not
necessarily included as major adverse
cardiac events requires a different ap-
proach and is illustrated for some GLP-1
receptor agonists, which tend to slightly
increase heart rate (sharp cardiological
intake of breath) but decrease blood
pressure slightly (possible cardiological
sigh of relief). GLP-1 receptors were
identiﬁed in the vasculature and myocar-
dium, so small bespoke safety studies
Figure 2dFDA guidance for industry for a meta-analysis of phase 2/3 data to evaluate CV risk
with new glucose-lowering therapies to treat type 2 diabetes. Based on ref. 44. *If overall beneﬁt-
risk analysis of the drug supports approval. RR, relative risk.
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were warranted. These studies focused on
corrected QT (QTc) interval duration,
which reassuringly showed no clinically
signiﬁcant alterations (50,51).
CANCERdWhereas CV events are
common in diabetes, cancers are uncom-
mon or rare but modestly increased (over-
all by ;40%) (52). Detection is often
delayed, and the attributing cause is com-
plicated by familial susceptibility; present
and prior obesity; history of exposure to
carcinogens, including smoking; and co-
morbid conditions. Allocation factors can
also confuse the evidence surrounding
malignancies; for example, an uneven
randomization for ethnicity, gender,
socioeconomic status, and educational
or geographical background can signiﬁ-
cantly inﬂuence the occurrence of can-
cers. Many patients who enter clinical
trials will not have previously received
the type of vigilant, frequent attention
of a health care professional inviting
them to report anything different since
the last visit. For example, rapid weight
loss during the early development trials
with orlistat was associated with an in-
creased detection of breast tumors (34,35)
and led to extensive studies of possible car-
cinogenicity, which had negative ﬁndings.
Additionally, protracted studies conﬁrmed
that the risk of breast tumors did not in-
crease with time but rather diminished,
suggesting that the combination of weight
loss and attentive clinical care in a trial set-
ting conferred a detection bias for breast
cancerda valuable beneﬁt for the patients
but a substantial delay for drug develop-
ment (34,35).
Pancreatic cancer
Deciding the proportionate level of cau-
tion to ascribe to a potential danger signal
is never straightforward. Take for exam-
ple the evidence for a putative link be-
tween incretin therapies (GLP-1 receptor
agonists and DPP-4 inhibitors) and pan-
creatitis, pancreatic ductal metaplasia,
and pancreatic cancer (28,53–56). Reports
of cases of acute pancreatitis in patients
receiving incretin therapies generated
awareness, which may have prompted
further similar reports and an accumula-
tion of cases in the pharmacovigilance
databases (57,58). However, the diag-
nosis of pancreatitis was not always con-
ﬁrmed; severity was highly variable; and
although the condition is known to be
more common among diabetic patients
than among the nondiabetic population,
estimated incidence rates have varied
widely from ,1 to ;5 per 1,000 patient-
years (13,17,57). Given a need to await
additional retrospective interrogation of
large databases, the labeling advice to
discontinue incretins in patients where
pancreatitis is suspected would seem
proportionate.
It is relevant to note here that phar-
macovigilance is an ongoing process to
monitor side effects, but a reported event
is not necessarily caused by the medicines
to which the report relates and should not
be interpreted as meaning that a medicine
is unsafe to use (57,58). Spontaneous re-
porting of suspected side effects should
not be used as a basis for estimating in-
cidence rates because they provide a
numerator without knowing the denom-
inator. Reporting rates are variable for
many reasons, events are not conﬁrmed,
and confounding factors may not be
taken into account (5,58).
An appreciation that pancreatitis
presents a risk for pancreatic cancer
(59), coupled with an animal study sug-
gesting that incretins might cause pancre-
atic duct cell proliferation, sparked
interest in a potential link between incre-
tins and pancreatic cancer (55,60). Addi-
tional studies in several animal species
could not conﬁrm the ductal proliferation
(61), but the FDA database showed more
cases of pancreatic cancer in patients who
had received certain incretins compared
Table 4dPostmarketing CV outcome studies with diabetes therapies
Trial Test agent Started Years No. pts Primary end point
TECOS Sitagliptin 2008 ;4 ;14,000 Composite of CV death,
NFMI, NFS, Angh
EXAMINE Alogliptin 2009 4.75 ;5,400 Composite of CV
death, NFMI, NFS
CANVAS Canagliﬂozin 2009 ;4 ;4,400 Composite of CV
death, NFMI, NFS
ACE Acarbose 2009 ;4 ;7,500 Composite of CV
death, NFMI, NFS
LEADER Liraglutide 2010 ;5 ;9,400 Composite of CV
death, NFMI, NFS
EXSCEL Exenatide QW 2010 ;5.5 9,500 Composite of CV
death, NFMI, NFS
SAVOR-TIMI 53 Saxagliptin 2010 ;4 16,500 Composite of CV
death, NFMI, NFS
CAROLINA Linagliptin 2010 8 6,000 Composite of CV death,
NFMI, NFS, Angh
ELIXA Lixisenatide 2010 ;4 ;6,000 Composite of CV death,
NFMI, NFS, Angh
NCT01131676 Empagliﬂozin 2010 ;4 ;7,000 Composite of CV
death, NFMI, NFS
NCT01042769 Aleglitazar 2010 ;4.5 ;7,000 Composite of CV
death, NFMI, NFS
REWIND Dulaglutide 2011 ;6.5 ;9,600 Composite of CV
death, NFMI, NFS
DECLARE-TIMI 58 Dapagliﬂozin 2013 ;6 17,150 Composite of CV
death, NFMI, NFS
Some studies started during phase 3. All are randomized and double blind in patients with type 2 diabetes
receiving usual care plus test agent and compared with placebo (or to comparator in CAROLINA). Recruited
patients include a high proportion with high CV risk (e.g., history of CV events) or, speciﬁcally, recently
experienced an acute coronary syndrome event. The primary end point is a composite of (time to) major
cardiovascular events. ACE, Acarbose Cardiovascular Evaluation Trial; Angh, unstable angina requiring
hospitalization; CANVAS, Canagliﬂozin Cardiovascular Assessment Study; CAROLINA, Cardiovascular
Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes; DECLARE-TIMI58,
Multicenter Trial to Evaluate the Effect of Dapagliﬂozin on the Incidence of Cardiovascular Events; ELIXA,
Evaluation of Cardiovascular Outcomes in Patients with Type 2 Diabetes After Acute Coronary Syndrome
During Treatment with AVE0010 (Lixisenatide); EXAMINE, Examination of Cardiovascular Outcomes:
Alogliptin versus Standard of Care; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; LEADER,
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; NCT, clinical trials
identiﬁer number; NFMI, nonfatal MI; NFS, nonfatal stroke; REWIND, Researching Cardiovascular Events
with aWeekly Incretin in Diabetes; SAVOR-TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded
in Patients with Diabetes Mellitus; TECOS: Trial to Evaluate Cardiovascular Outcomes with Sitagliptin.
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with other classes of diabetes drugs (62).
The problem of attempting numerical
analyses from spontaneous adverse event
reporting has already been noted, but
could this be a signal? Pancreatic cancer
is rare at ,0.1 per 1,000 patient-years. It
is slow to develop to detection, and unlike
other cancers, its occurrence tends to de-
crease with time after diagnosis of diabe-
tes (62). So, numbers and time may
preclude an early resolution from post-
marketing trials. In general, clinical expe-
rience to date does not appear to support
an association of incretins with pancre-
atic cancer (63,64), but the issue has
emphasized that procedures for extrapo-
lating preclinical signals to clinical situa-
tions and projecting possible clinical
signals into future clinical events are still
tenuous.
Thyroid cancer
An example of scrambled signals is that
of a purported link between liraglutide
and thyroid C-cell medullary cancer.
Thyroid C cells of rats and mice express
high concentrations of GLP-1 receptors
and respond to high concentrations of
GLP-1 receptor agonists with excess cal-
citonin secretion and C-cell hyperplasia
(65). In clinical studies, liraglutide
slightly raised calcitonin concentrations,
but human thyroid C cells have a low ex-
pression of GLP-1 receptors, and calcito-
nin concentrations were not elevated to
an extent that is considered a signal for
medullary C-cell cancer (66). Bearing in
mind that such cancers are rare, ;600–
1,000 annually in the U.S., a clinical trial
is not an option. Sensibly, the FDA ex-
plained its reasoning in a high-proﬁle
journal, a move that was similarly useful
with regard to metformin and lactic aci-
dosis some 15 years ago (67).
Bladder cancer
Interpreting preclinical and clinical sig-
nals suggestive of a bladder cancer risk
with pioglitazone is still difﬁcult after
more than one decade of accumulated
evidence. Animal studies suggested a me-
tabolite that could irritate the urothelium
and cause localized hyperplasia (68),
and a major clinical trial (PROactive [Pro-
spective Pioglitazone Clinical Trial in
Macrovascular Events]) noted an in-
creased occurrence of bladder tumors
(25), but no excess was observed after a
6-year observational follow-up (69). Sev-
eral meta-analyses based around ﬁve large
cohort studies totaling .2.3 million
diabetic patients have shown a small
increased risk of bladder tumors (1.17–
2.22 fold), with a slightly higher risk
(1.3–1.4 fold) in those exposed for .2
years (70,71). Given a bladder cancer in-
cidence of ;0.5 per 1,000 patient-years
in diabetes, these studies indicated an in-
creased risk of ;0.1 per 1,000 patient-
years. However, within these studies,
there were difﬁculties in assessing prior
exposure to key risk factors, including
smoking, the time taken for these cancers
to develop, and variability in detection.
Additionally, the risk of some other can-
cers may have been reduced in patients
receiving pioglitazone, leaving no appar-
ent overall cancer imbalance (72). Some
countries in Europe decided to discon-
tinue pioglitazone, but the EMA has not
endorsed this, preferring to modify the
label to recommend avoidance of the
drug in patients with active bladder can-
cer and in those at high risk (73). Thus,
we have another example of varying inter-
pretations by different expert groups assess-
ing the same information and weighing the
extent of adverse signals and events against
the beneﬁts.
Another cancer question has been raised
for the sodium glucose cotransporter-2
inhibitor dapagliﬂozin, which was re-
cently approved in Europe and Australia.
Although there was no evidence of mu-
tagenicity or carcinogenicity in preclin-
ical trials and no overall imbalance in
malignancies during the development
program, there were increases in breast,
prostate, and bladder cancers (74). Given
the weight loss associated with this agent,
the detection bias discussed for orlistat
may apply, and the prostate cancers
(mostly well advanced) were generally
discovered early in the trials when scru-
tiny of urinary phenomena brought to
attention hematuria and urination difﬁ-
culties. A history of hematuria recently
before or at randomization was recorded
for 7 of 10 cases of bladder cancer; these
cancers were mostly detected too early
and were too advanced to have originated
after treatment with dapagliﬂozin. Whe-
ther persistently high glucose in the urine
could promote growth of preexisting tu-
mors is not entirely excluded, but exten-
sive preclinical studies have not shown a
signal, and patients with familial renal
glucosuria do not appear to experience
detrimental effects of lifelong glucosuria
(75).
Insulin and cancer
The evidence with regard to insulin and
cancer is far too extensive and controversial
to dissect here (52,76–79). There are so
many confounders in most of the studies
that it is possible to question and criticize
any interpretation. Thus are the shaky
foundations upon which adverse events
have to be assessed. Insulin is not of itself
carcinogenic, but through its interactions
with the different isoforms of the insulin
receptor and the IGF1 receptor, it stands
under suspicion of promoting tumor
growth. By way of summary and exclud-
ing less solid evidence, it appears that re-
placement amounts of human insulin do
not increase risk. However, this conclu-
sion cannot yet be extended to the mas-
sive pharmacological doses needed for
highly insulin resistant individuals who
likely carry an abundance of other risks
and for whom alternative glucose-lower-
ing therapies are not available. Analog in-
sulins in present use do not appear to be
any less safe in this context, as most re-
cently reported by the ORIGIN (Out-
come Reduction with Initial Glargine
Intervention) trial (80). For the record,
most circulating glargine is dearginated
to a low-afﬁnity binding metabolite
(M1) before it meets tissue receptors
(79,81). Also recall that the highest en-
dogenous exposure to insulin is in the
liver, and this is likely to have been exag-
gerated during a hyperinsulinemic predi-
abetes period, whereas subcutaneous
administration of insulin alters the dispo-
sition of insulin in favor of other tissues.
A consensus report of the American Di-
abetes Association and American Cancer
Society reasonably advises that on the
balance of current evidence, cancer risk
should not be a major factor in choosing
between available diabetes therapies for
the average patient, although patients
with a very high risk for cancer occurrence
or recurrence may require more careful
consideration (82).
BONE FRACTURESdThiazolidine-
diones have been associated with declining
bone mineral density and increased risk of
bone fractures, especially in older women
(13,83–85). Although thiazolidinediones
continue to receive careful clinical investi-
gation, they provide a further example of
the importance of preclinical mechanistic
studies. In vitro and animal data have
shown effects of peroxisome proliferator-
activated receptor-g (PPARg) agonists on
the differentiation pathways of various
cell types populating bone (86). Although
the various biomarkers of bone health can
be used effectively for diagnosis and thera-
peutic monitoring, there are considerable
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limitations to their predictive value for the
individual, and interpretation of small
changes during preregistration trials re-
mains uncertain (87,88).
CONCLUSIONSdA particular chal-
lenge when interpreting adverse signals in
clinical trials is the need to extrapolate to a
real-world environment where patient
populations may be more diverse, pre-
scribers less specialized, and monitoring
less conscientious. Faint signals from pre-
registration trials can take a decade or
more to reveal their clinical consequences
and often are unpredictable and con-
founded by allocation and detection
bias, prior exposure to risk factors
(known and unknown), and limitations
of time and numbers.
The need to revise the label or even
withdraw a drug should not be viewed
as a failure of foresight but, rather, as the
mark of a vigilant and responsive regula-
tory process. To minimize risk, new
medicines have explicit exclusions rein-
forced with temporary (and sometimes
permanent) black box warnings that per-
mit availability to deﬁned patient popu-
lations while allowing time for separate
controlled studies with more vulnerable
or different subpopulations. Mounting
pressures to make all clinical trial in-
formation available and all databases ac-
cessible to everyone will introduce
opportunities for furthermisinterpretation.
Transparency requires responsibility, but
beneﬁt and risk often are a judgment of
probability, and revisions have to be ac-
cepted without prejudice as new informa-
tion emerges. The teachings of the 16th
century Swiss-German physician Paracel-
sus remind us that no chemical is abso-
lutely safe, and the difference between a
medicine and a poison can be the dose.
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